How is the ProVent risk score calculated for a patient on invasive mechanical ventilation for more than 21 days, and how does the resulting score guide prognosis and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ProVent Risk Score: Calculation and Clinical Application

The ProVent score is calculated on day 21 of mechanical ventilation using four simple variables: age (≥50 years = 2 points, ≥65 years = 3 points), platelet count (≤150 × 10⁹/L = 2 points), vasopressor requirement (2 points), and hemodialysis requirement (2 points), with scores ranging from 0-5 that directly predict 1-year mortality from 15% to 97%. 1, 2

Score Calculation

The ProVent score assigns points based on the following criteria measured specifically on day 21 of mechanical ventilation:

  • Age: 0 points (18-49 years), 2 points (50-64 years), 3 points (≥65 years)
  • Platelet count: 2 points if ≤150 × 10⁹/L, 0 points if >150 × 10⁹/L
  • Vasopressor use: 2 points if required on day 21
  • Hemodialysis/renal replacement therapy: 2 points if required on day 21

The total score ranges from 0 to 5 points 2.

Prognostic Stratification

The score demonstrates excellent discrimination with clear mortality thresholds:

  • Score 0: 15% 1-year mortality (low risk)
  • Score 1: 27-54% 1-year mortality (moderate risk)
  • Score 2: 57-69% 1-year mortality (moderate-high risk)
  • Score 3: 66-76% 1-year mortality (high risk)
  • Score ≥4: 76-97% 1-year mortality (very high risk)

The model achieved an area under the receiver operating characteristic curve of 0.76-0.82 across multiple validation studies, indicating good discriminatory ability 1, 2, 3, 4.

Clinical Application for Management

For Scores 0-1 (Low Risk, <30% mortality):

  • Proceed aggressively with weaning protocols as these patients have reasonable survival prospects
  • Consider early tracheostomy if not already performed to facilitate weaning
  • Implement protocolized rehabilitation with early mobilization 5
  • Plan for discharge to rehabilitation facilities with ventilator weaning capabilities

For Score 2 (Moderate-High Risk, 57-69% mortality):

  • Initiate detailed goals-of-care discussions with patient/surrogates about realistic expectations
  • Continue aggressive treatment but establish clear time-limited trial parameters
  • Reassess weekly for improvement in modifiable factors (platelet count, vasopressor/dialysis requirements)
  • If no improvement by day 28-35, strongly consider transition to comfort-focused care

For Scores ≥3 (High Risk, >70% mortality):

  • Strongly recommend palliative care consultation and goals-of-care discussions
  • Among patients with score ≥3, only 3-14% achieve direct discharge home 2
  • For score ≥4, consider recommending comfort-focused care given 86-97% 1-year mortality
  • If family insists on continued aggressive care, establish clear milestones for reassessment within 7-14 days

Important Caveats and Limitations

The score has demonstrated geographic and temporal generalizability across multiple international cohorts 3, 4, but one Austrian validation study found miscalibration requiring recalibration 6. The original model may overestimate survival in some populations.

Age emerged as the strongest independent predictor across all validation studies 3, 4, while thrombocytopenia was particularly predictive in some cohorts 4.

The score can be applied earlier at day 14 of mechanical ventilation with similar accuracy (AUC 0.75), allowing earlier prognostic discussions 3. However, the original validation was at day 21, so day 14 application requires additional clinical judgment.

Quality of life considerations: Among survivors requiring prolonged mechanical ventilation, those successfully weaned had significantly more quality-adjusted life days than unsuccessfully weaned patients (median 73 vs 0 days over 6 months) 7. Even successfully weaned patients experienced reduced health-related quality of life and required multiple care transitions (median 4 transitions) 7.

Pitfalls to Avoid

  • Do not apply the score before day 21 (or day 14 at earliest) of mechanical ventilation—earlier application lacks validation
  • Do not use the score in isolation—it should inform but not replace comprehensive clinical judgment and patient/family preferences
  • Recognize that the score predicts 1-year mortality, not ICU or hospital mortality—some patients will survive hospitalization but die within the year
  • The score does not account for neurological status, functional capacity, or pre-existing comorbidities beyond those captured in the four variables
  • Premature withdrawal of support based solely on the score is inappropriate—use it to frame realistic discussions, not to unilaterally limit care

References

Related Questions

In a febrile female patient whose creatine kinase (CK) and serum creatinine have returned to normal, how long is she expected to remain on mechanical ventilation?
What are the side effects of long-term ventilation and how are they managed?
How can mild ascites lead to a massive pleural effusion?
What is the recommended dosage of norfloxacin‑tinidazole (Norflox TZ) for adults, and how should the dose be adjusted in patients with severe renal impairment?
In an older adult with dementia who stays awake at night and experiences nighttime falls, currently taking nightly olanzapine 10 mg and tamsulosin 0.4 mg, with stable vital signs and bilateral lower‑extremity edema being treated with ceftriaxone (Rocephin) 1 g twice daily, and whose falls began before the infection, what are the likely contributors to the falls and how should the medication regimen be adjusted to reduce fall risk?
How should anticoagulation be managed in a post‑craniotomy patient with an INR of 3 who is taking warfarin 5 mg daily?
Should the patient be switched from sotalol 80 mg twice daily to bisoprolol because of a QTc interval of 500 ms?
Is sultamicillin (ampicillin/sulbactam pro‑drug) an appropriate oral alternative for a stable patient with a controlled wound infection who cannot receive amoxicillin‑clavulanate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.